Melinta Therapeutics, a New Haven, Conn-based antibiotics developer, raised $70m in a Series “3” financing.
The round was led by Vatera Healthcare Partners, with participation from existing and new investors (Falcon Flight).
Led by Mary Szela, CEO, Melinta Therapeutics is dedicated to the discovery, development and commercialization of antibiotics to overcome drug-resistant, life-threatening infections.
The company intends to use the funds to advance delafloxacin, a differentiated fluoroquinolone, through an ongoing Phase 3 study of a single oral dose in individuals with uncomplicated gonorrhea, to the submission of a New Drug Application (NDA) in late 2014, two ongoing Phase 3 trials for the treatment of acute bacterial skin and skin structure infections (ABSSSI) and the selection of lead candidates from its RX-04 research program.
The RX-04 program is focused on the creation of novel molecular structures and selection of unique candidates that target novel binding sites on the bacterial ribosome. Melinta plans to select lead candidates and advance IND-enabling studies in 2014 for the treatment of serious and life-threatening infections caused by multi-drug resistant Gram-negative microbes.